- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06055920
PEERLESS II-undersøgelsen
PEERLESS II: RCT af FlowTriever vs. Antikoagulation alene i lungeemboli
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Aalst, Belgien
- Onze Lieve Vrouwziekenhuis
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Canada, V3L 3W7
- Royal Columbian Hospital
-
Surrey, British Columbia, Canada, V3V 1Z2
- Surrey Memorial Hospital
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital
-
-
-
-
-
Aarhus, Danmark, 8200
- Aarhus University Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35243
- Brookwood Medical Center
-
Birmingham, Alabama, Forenede Stater, 35205
- UAB Division of Cardiovascular Disease
-
-
California
-
Pasadena, California, Forenede Stater, 91105
- Huntington Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado, Denver
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06520
- Yale University
-
-
Florida
-
Largo, Florida, Forenede Stater, 33770
- HCA FL Largo Medical Center
-
Orlando, Florida, Forenede Stater, 32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
-
Michigan
-
Lansing, Michigan, Forenede Stater, 48910
- McLaren Greater Lansing
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, Forenede Stater, 65804
- Mercy Hospital Springfield
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68105
- Nebraska Medical Center
-
-
New Jersey
-
Camden, New Jersey, Forenede Stater, 08103
- Virtua Health
-
-
New York
-
Buffalo, New York, Forenede Stater, 14203
- SUNY, The University of Buffalo/Gates Vascular
-
New York, New York, Forenede Stater, 10075
- Northwell Health
-
Rochester, New York, Forenede Stater, 14642
- University of Rochester Medical Center
-
Stony Brook, New York, Forenede Stater, 11794
- Stony Brook University Hospital
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Forenede Stater, 44195
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Forenede Stater, 43210
- Ohio State University - Wexner Medical Center
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forenede Stater, 18015
- St. Luke's University Hospital
-
Erie, Pennsylvania, Forenede Stater, 16507
- UPMC Hamot
-
Erie, Pennsylvania, Forenede Stater, 16505
- AHN Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Forenede Stater, 17101
- UPMC Harrisburg
-
Philadelphia, Pennsylvania, Forenede Stater, 19144
- Thomas Jefferson University
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- The University of Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- UPMC Heart and Vascular Institute
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Allegheny Health Network Research Institute
-
York, Pennsylvania, Forenede Stater, 17403
- Wellspan York Hospital
-
-
Tennessee
-
Brentwood, Tennessee, Forenede Stater, 37027
- HCA Tristar
-
Knoxville, Tennessee, Forenede Stater, 37920
- UTMC Knoxville
-
Nashville, Tennessee, Forenede Stater, 37203
- Ascension Saint Thomas Hospital
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- Parkland Hospital
-
Fort Worth, Texas, Forenede Stater, 76104
- Texas Health Harris Methodist Hospital
-
San Antonio, Texas, Forenede Stater, 78229
- Methodist Main Hospital
-
Temple, Texas, Forenede Stater, 76508
- Baylor Scott & White - Temple
-
-
Virginia
-
Falls Church, Virginia, Forenede Stater, 22042
- Inova Fairfax
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Charleston Area Medical Center
-
Morgantown, West Virginia, Forenede Stater, 26506
- West Virginia University Ruby Memorial Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aurora Saint Luke's Medical Center
-
-
-
-
-
Lille, Frankrig
- CHU Lille
-
Lyon, Frankrig
- Hôpital Louis Pradel
-
Marseille, Frankrig
- Hôpital Nord Marseille
-
Marseille, Frankrig
- AP-HM Hopital La Timone
-
-
-
-
-
Basel, Schweiz
- Universitaetsspital Basel
-
Bern, Schweiz
- Universitätsspital Bern
-
Lucerne, Schweiz
- Luzerner Kantonsspital
-
-
-
-
-
Madrid, Spanien
- Hopital Clinico Universitario San Carlos
-
-
-
-
-
Augsburg, Tyskland
- University Hospital Augsburg
-
Bad Krozingen, Tyskland
- Universitäts-Herzzentrum Bad Krozingen
-
Berlin, Tyskland
- Charité Campus Virchow Clinic - Klinik fuer Radiologie
-
Berlin, Tyskland
- Unfall Krankenhaus Berlin
-
Cologne, Tyskland
- University Hospital Cologne
-
Dresden, Tyskland
- HerzZentrum Dresden Universitaetsklinik
-
Düsseldorf, Tyskland
- Universitaetsklinikum Dὒsseldorf
-
Essen, Tyskland
- Universitaetsklinikum Essen
-
Essen, Tyskland
- Elisabeth Hospital GmbH
-
Frankfurt, Tyskland
- CCB Frankfurt
-
Hamburg, Tyskland
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, Tyskland
- University Hospital - Heidelberg
-
Kaiserslautern, Tyskland
- Westpfalz Klinikum
-
Munich, Tyskland
- Klinikum rechts der Isar (TUM)
-
Munich, Tyskland
- Ludwig Maximilians-University
-
Regensburg, Tyskland
- University Hospital Regensburg
-
Villingen-Schwenningen, Tyskland
- Schwarzwald-Baar-Klinikum
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Age at enrollment ≥ 18 years
-
Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality
-
RV dysfunction, as defined as one or more of the following: RV/LV ratio ≥ 0.9 or RV dilation or hypokinesis
-
At least two additional risk factors, identified by at least one measure in two separate categories noted below:
a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate > 100 bpm b. Biomarker: i. Elevated* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol/L * Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation < 90% on room air ii. Supplemental O2 requirement ≥ 4 L/min iii. Respiratory rate ≥ 20 breaths/min iv. mMRC score > 0
-
Symptom onset within 14 days of confirmed PE diagnosis
-
Willing and able to provide informed consent
Exclusion Criteria:
-
Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin
-
Presentation with hemodynamic instability* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following
- Cardiac arrest OR
- Systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR
- Systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.
-
Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
-
Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot)
-
End stage medical condition with life expectancy < 3 months, as determined by the Investigator
-
Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
-
Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1
-
If objective testing was performed*, estimated RV systolic pressure > 70 mmHg on standard of care echocardiography * If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion
-
Administration of advanced therapies (thrombolytic bolus, thrombolytic drip/infusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment
-
Ventricular arrhythmias refractory to treatment at the time of enrollment
-
Known to have heparin-induced thrombocytopenia (HIT)
-
Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling
-
Subject is currently pregnant
-
Subject has previously completed or withdrawn from this study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: FlowTriever
Mechanical thrombectomy for pulmonary embolism using the FlowTriever System. |
Mechanical Thrombectomy for pulmonary embolism |
|
Aktiv komparator: Anticoagulation
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
Tidsramme: through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
|
through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Alle årsager og PE-relateret dødelighed
Tidsramme: Ved 30 og 90 dage
|
Ved 30 og 90 dage
|
|
|
Alle årsager og PE-relaterede genindlæggelser
Tidsramme: Ved 30 og 90 dage
|
Ved 30 og 90 dage
|
|
|
6 minutters gåafstand
Tidsramme: Ved 1-måneders besøg
|
Ved 1-måneders besøg
|
|
|
RV/LV-forhold
Tidsramme: Ved det 48 timer lange besøg
|
Ved det 48 timer lange besøg
|
|
|
Post-PE Impairment Diagnosis (PPEI)
Tidsramme: Gennem det 3-måneders besøg
|
Gennem det 3-måneders besøg
|
|
|
Composite clinical endpoint constructed as a win ratio hierarchy of the following three components, assessed post randomization:
Tidsramme: up to 30 days
|
|
up to 30 days
|
|
Clinical deterioration
Tidsramme: Through discharge or up to 30 days after randomization, whichever is sooner
|
defined by hemodynamic or respiratory worsening |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Bailout therapy
Tidsramme: Through discharge or up to 30 days after randomization, whichever is sooner
|
either after a deterioration or after documented failure to progress, |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Major Bleeding, defined by the Bleeding Academic Research Consortium (BARC), level 3b, 3c, 5a, or 5b
Tidsramme: At 30 and 90 days
|
3b: Overt bleeding plus hemoglobin drop of ≥ 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); bleeding requiring intravenous vasoactive agents 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), subcategories confirmed by autopsy or imaging or lumbar puncture, intraocular bleed compromising vision. 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation |
At 30 and 90 days
|
|
Dyspnea severity by mMRC score
Tidsramme: At the 48-hour, 1-month, and 3-month visits
|
0, no breathlessness except on strenuous exercise;
|
At the 48-hour, 1-month, and 3-month visits
|
|
PE-related quality of life, by PEmb-QoL
Tidsramme: At the 1- and 3-month visits
|
Pulmonary Embolism Quality of Life: (higher = better) |
At the 1- and 3-month visits
|
|
General health-related quality of life, by EQ-5D-5L
Tidsramme: At the 1- and 3-month visits
|
Higher score = worse |
At the 1- and 3-month visits
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Jay Giri, MD, Penn Medicine
- Ledende efterforsker: Bernhard Gebauer, MD, Charité University Hospital Berlin
- Ledende efterforsker: Felix Mahfoud, MD, Universitaetsspital Basel
- Ledende efterforsker: Frances Mae West, MD, Jefferson Health
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 23-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .